Abiopharma

🔍 Schilke Tobin (Executive)

Company: Crinetics Pharmaceuticals, Inc. (CRNX)

Report Date: 2026-08-20

Detailed Transactions and Holdings:

• Acquired 471 shares of Common Stock (Direct)
  Date: 2026-08-20 | Code: A | equity_swap_involved: 0 | shares_owned_after: 79,427.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on September 1, 2027.
• F2: Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.